Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu 177 dihydroxybenzylidene iminodiacetic acid
- Development stage
- Preclinical
- Lead developer
- Bhabha Atomic Research Centre
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Lutetium Lu 177 dihydroxybenzylidene iminodiacetic acid (177Lu-HBIDA) is an experimental therapeutic radiopharmaceutical investigated primarily for the palliation of bone pain in patients with skeletal metastases. The agent consists of the beta-emitting radioisotope lutetium-177 complexed with the Schiff base ligand N-(2,4-dihydroxybenzylidene)iminodiacetic acid (HBIDA). HBIDA serves as a bone-seeking vector, exhibiting high affinity for hydroxyapatite, the primary mineral component of bone. Upon intravenous administration, the complex localizes to areas of active bone remodeling and osteoblastic activity, common in metastatic bone disease. The localized decay of lutetium-177 releases beta particles that deliver targeted cytotoxic radiation to tumor cells and nerve endings within the bone matrix, thereby reducing pain and potentially inhibiting tumor growth. Research on this compound has been notably conducted by the Bhabha Atomic Research Centre (BARC) in India.
- Other names
- lutetium (177Lu) HBIDA177Lu-labeled N-(2,4-dihydroxybenzylidene)iminodiacetic acidlutetium-177 dihydroxybenzylidene iminodiacetic acidlutetium177 dihydroxybenzylidene iminodiacetic acidlutetium 177 dihydroxybenzylidene iminodiacetic acid
02
Targets
DNA
Beyond the preview
Go deeper on lutetium Lu 177 dihydroxybenzylidene iminodiacetic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu 177 dihydroxybenzylidene iminodiacetic acid.